Multicentre randomised controlled trial comparing the safety in the first 12 h, efficacy and maternal satisfaction of a double balloon catheter and prostaglandin pessary for induction of labour.

OBJECTIVE: To evaluate the safety in the first 12 h, efficacy and maternal satisfaction of a double balloon catheter (DBC) with vaginal prostaglandin (PGE) for induction of labour (IOL). METHODS: We conducted a multicentre randomised controlled study of 420 patients from 1st January 2016 to 31st December 2017 to evaluate the use of DBC in IOL in an Asian population looking at the adverse effects in the first 12 h after insertion. Women were assigned randomly to cervical ripening with either a DBC or a prostaglandin pessary. The adverse events in the 12 h after DBC or first prostaglandin inserted, the efficacy of a DBC to a prostaglandin in labour induction and maternal satisfaction were evaluated. RESULTS: There were significantly less women with uterine hyperstimulation in the DBC (2 vs 24, p ≤ 0.0001) compared to the prostaglandin group. There were no women with uterine hyperstimulation and non-reassuring foetal status in the DBC while there were 5 women with uterine hyperstimulation and foetal distress in the prostaglandin group. Use of entonox was significantly less in the DBC group (p = 0.009). There were no significant differences in both groups in caesarean section, vaginal deliveries and time to delivery, although significant less time was needed to achieve cervical os dilation more than 4 cm in the DBC group (p ≤ 0.0001). Neonatal birth outcomes were similar. Women's pain scores were similar for both methods. 80.1% of women allocated the DBC and 76.8% of women allocated the PGE were keen to recommend their method of induction. CONCLUSION: Double balloon catheter remains a good alternative method for inducing women in view of a good safety profile with low risk of hyperstimulation and high maternal satisfaction. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02620215.

IoT-based external attacks aware secure healthcare framework using blockchain and SB-RNN-NVS-FU techniques.

BACKGROUND: In recent times, there has been widespread deployment of Internet of Things (IoT) applications, particularly in the healthcare sector, where computations involving user-specific data are carried out on cloud servers. However, the network nodes in IoT healthcare are vulnerable to an increased level of security threats. OBJECTIVE: This paper introduces a secure Electronic Health Record (EHR) framework with a focus on IoT. METHODS: Initially, the IoT sensor nodes are designated as registered patients and undergo initialization. Subsequently, a trust evaluation is conducted, and the clustering of trusted nodes is achieved through the application of Tasmanian Devil Optimization (STD-TDO) utilizing the Student's T-Distribution. Utilizing the Transposition Cipher-Squared random number generator-based-Elliptic Curve Cryptography (TCS-ECC), the clustered nodes encrypt four types of sensed patient data. The resulting encrypted data undergoes hashing and is subsequently added to the blockchain. This configuration functions as a network, actively monitored to detect any external attacks. To accomplish this, a feature reputation score is calculated for the network's features. This score is then input into the Swish Beta activated-Recurrent Neural Network (SB-RNN) model to classify potential attacks. The latest transactions on the blockchain are scrutinized using the Neutrosophic Vague Set Fuzzy (NVS-Fu) algorithm to identify any double-spending attacks on non-compromised nodes. Finally, genuine nodes are granted permission to decrypt medical records. RESULTS: In the experimental analysis, the performance of the proposed methods was compared to existing models. The results demonstrated that the suggested approach significantly increased the security level to 98%, reduced attack detection time to 1300 ms, and maximized accuracy to 98%. Furthermore, a comprehensive comparative analysis affirmed the reliability of the proposed model across all metrics. CONCLUSION: The proposed healthcare framework's efficiency is proved by the experimental evaluation.

Mass spectrometric discovery and selective reaction monitoring (SRM) of putative protein biomarker candidates in first trimester Trisomy 21 maternal serum.

The accurate diagnosis of Trisomy 21 requires invasive procedures that carry a risk of miscarriage. The current state-of-the-art maternal serum screening tests measure levels of PAPP-A, free bhCG, AFP, and uE3 in various combinations with a maximum sensitivity of 60-75% and a false positive rate of 5%. There is currently an unmet need for noninvasive screening tests with high selectivity that can detect pregnancies at risk, preferably within the first trimester. The aim of this study was to apply proteomics and mass spectrometry techniques for the discovery of new putative biomarkers for Trisomy 21 in first trimester maternal serum coupled with the immediate development of quantitative selective reaction monitoring (SRM) assays. The results of the novel workflow were 2-fold: (1) we identified a list of differentially expressed proteins in Trisomy 21 vs Normal samples, including PAPP-A, and (2) we developed a multiplexed, high-throughput SRM assay for verification of 12 new putative markers identified in the discovery experiments. To narrow down the initial large list of differentially expressed candidates resulting from the discovery experiments, we incorporated receiver operating characteristic (ROC) curve algorithms early in the data analysis process. We believe this approach provides a substantial advantage in sifting through the large and complex data typically obtained from discovery experiments. The workflow efficiently mined information derived from high-resolution LC-MS/MS discovery data for the seamless construction of rapid, targeted assays that were performed on unfractionated serum digests. The SRM assay lower limit of detection (LLOD) for the target peptides in a background of digested serum matrix was approximately 250-500 attomoles on column and the limit of accurate quantitation (LOQ) was approximately 1-5 femtomoles on column. The assay error as determined by coefficient of variation at LOQ and above ranged from 0 to 16%. The workflow developed in this study bridges the gap between proteomic biomarker discovery and translation into a clinical research environment. Specifically, for Trisomy 21, the described multiplexed SRM assay provides a vehicle for high-throughput verification of these, and potentially other, peptide candidates on larger sample cohorts.

Fetal RHD genotyping in maternal plasma at 11-13 weeks of gestation.

OBJECTIVE: To examine the feasibility of fetal RHD genotyping at 11-13 weeks' gestation from analysis of circulating cell-free fetal DNA (ccffDNA) in the plasma of RhD negative pregnant women using a high-throughput robotic technique. METHODS: Stored plasma (0.5 ml) from 591 RhD negative women was used for extraction of ccffDNA by a robotic technique. Real-time quantitative polymerase chain reaction (PCR) with probes for exons 5 and 7 of the RHD gene was then used to determine the fetal RHD genotype, which was compared to the neonatal RhD phenotype. RESULTS: In total there were 502 (85.7%) cases with a conclusive result and 84 (14.3%) with an inconclusive result. The prenatal test predicted that the fetus was RhD positive in 332 cases and in all of these the prediction was correct, giving a positive predictive value of 100% (95% CI 96.8-100). The test predicted that the fetus was RhD negative in 170 cases and in 164 of these the prediction was correct, giving a negative predictive value for RhD positive fetuses of 96.5% (95% CI 93.7-99.2). CONCLUSION: The findings demonstrate the feasibility and accuracy of non-invasive fetal RHD genotyping at 11-13 weeks with a high-throughput technique.

Are serum protein biomarkers derived from proteomic analysis useful in screening for trisomy 21 at 11-13 weeks?

OBJECTIVE: The aim of this study is to identify potential biomarkers for fetal trisomy 21 from previous publications using proteomic techniques and examine the potential value of such biomarkers in early screening for this aneuploidy. METHODS: This was a case-control study of 25 pregnancies with fetal trisomy 21 and 50 euploid controls undergoing first-trimester screening for aneuploidies by a combination of maternal age, fetal nuchal translucency (NT) thickness and maternal serum free ß-human chorionic gonadotrophin (ß-hCG) and pregnancy-associated plasma protein-A (PAPP-A). The maternal serum concentrations of afamin, apolipoprotein E, clusterin, ceruloplasmin, epidermal growth factor, fetuin-A, pigment epithelium-derived factor glycoprotein and transthyretin were determined using an ELISA and compared in the euploid and trisomy 21 groups. RESULTS: In pregnancies with fetal trisomy 21, the median maternal age, fetal NT thickness and serum free ß-hCG were increased, whereas serum PAPP-A was decreased. However, there were no significant differences between cases and controls in any of the biomarkers. CONCLUSION: Proteins identified as potential biomarkers for trisomy 21 using proteomic techniques have not been found to be useful in early screening for this aneuploidy.